title: The effect of risedronate treatment on serum osteoprotegerin and bone marker levels in postmenopausal women with osteoporosis.
abstract: BACKGROUND
  To evaluate the effect of risedronate treatment on osteoprotegerin (OPG), C-terminal cross-linking telopeptide of type 1 collagen (CTX), osteocalcin (OC), and deoxypyridinoline (DPD).
  
  
  METHODS
  Eighty postmenopausal osteoporotic patients were randomized into two groups. In first group, patients received 35?mg of risedronate once a week and calcium with vitamin D per day. In second group, patients received only calcium with vitamin D per day. Bone turnover markers were measured at baseline, 1st, 3rd and 6th month.
  
  
  RESULTS
  OPG levels were significantly reduced at 1st and 6th month of treatment in both groups, but no statistically significant difference was detected between groups. In the group treated with risedronate, difference in CTX level was observed at 3rd month of treatment, while a difference in DPD and OC levels were observed at 6th month of treatment. The baseline OPG levels correlated with age, menopause duration, and CTX levels. There was no correlation between OPG levels and the levels of the other markers during treatment.
  
  
  CONCLUSIONS
  The present study showed that using risedronate in treatment of postmenopausal osteoporosis causes no specific changes in OPG levels; therefore, in contrast to some of the studies in the literature OPG may not be useful marker in monitoring of bisphosphonate.
authors.affiliation: Department of Physical Medicine and Rehabilitation, Marmara University School of Medicine, Istanbul, Turkey. evrimkaradag4@hotmail.com
authors.forename: Evrim
authors.initials: E
authors.lastname: Karadag-Saygi
authors.forename: Gulseren
authors.initials: G
authors.lastname: Akyuz
authors.forename: Peyman
authors.initials: P
authors.lastname: Bizargity
authors.forename: Pinar
authors.initials: P
authors.lastname: Ay
mesh_terms: D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood* / Q000378:metabolism; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D001842:Bone and Bones / Q000187:drug effects* / Q000378:metabolism; D002118:Calcium / Q000008:administration & dosage / Q000494:pharmacology; D012968:Etidronic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D005269:Femur; D005500:Follow-Up Studies; D006801:Humans; D008159:Lumbar Vertebrae; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000097:blood* / Q000188:drug therapy / Q000378:metabolism; D053244:Osteoprotegerin / Q000097:blood*; D000068296:Risedronic Acid; D014807:Vitamin D / Q000008:administration & dosage / Q000494:pharmacology
chemical_list: D015415:Biomarkers; D050071:Bone Density Conservation Agents; D053244:Osteoprotegerin; C506030:TNFRSF11B protein, human; D014807:Vitamin D; D000068296:Risedronic Acid; D012968:Etidronic Acid; D002118:Calcium